Age-Related Macular Degeneration (AMD) is the leading cause of irreversible blindness in much of the world, and with aging populations and increasing lifespans, is growing rapidly. One in four individuals has a diagnosis of AMD by age 75 years, and there are no treatments for “dry” AMD. Major hurdles include AMD’s complex biology, difficult clinical trial design, and the ultimate need for… · More long-term drug delivery to the eye.
Our lead candidate, TMi-018, is a first-in-class transcriptional modulator that converts aggressive macrophages back to neutral. TMi-018 is dose-dependently efficacious in pre-clinical models, reducing patches of tissue loss that characterize late blinding disease. It is a small synthetic compound demonstrated suitable for sustained release within the eye, allowing us to avoid repeated monthly injections. TMi-018 is successfully patented by us for ophthalmic indications in the US, EU, Australia, China and Israel.